Clinical Trial

A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma

Study acronym: MODIFY
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The aim of this study is to evaluate the efficacy of depemokimab administered as an adjunctive therapy, in participants with Type 2 asthma at risk of exacerbations compared to the guideline recommended standard of care (SoC).
Protocol Amendment History 2 changes
critical Recruitment opened 2026-06-26
notable Trial sites expanded: 0 -> 8 locations 2026-06-26
Trial Details
NCT Number NCT07456033
Lead Sponsor GlaxoSmithKline
Conditions Asthma
Enrollment 456 participants
Start Date 2026-03-13
Primary Completion 2030-07-08 (estimated)
Study Completion 2030-07-08 (estimated)
Updated on ClinicalTrials.gov 2026-06-25